Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome

Menno T. Zomerhuis, Shahid M. Hussain, Richard A. Feelders, Aart Jan Van Der Lely, Wouter W. De Herder

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We have investigated the acute and sustained hemodynamic effects of octreotide on hepatic metastases of midgut carcinoids using contrast-enhanced dynamic magnetic resonance imaging (MRI). Seven patients with the carcinoid syndrome and metastasized midgut carcinoid tumors underwent functional dynamic multi-phase gadolinium-enhanced MRI of selected liver metastases at baseline and 60 min after the subcutaneous (s.c.) administration of 100 μg octreotide, and also after 3 months with three times daily (t.i.d.) 100 μg octreotide s.c. Baseline MRIs showed the typical aspect of carcinoid liver metastases with a very bright signal on the T2-weighted sequences and intense enhancement in the arterial phase after injection of gadolinium-diethylenetriamine-pentaacetate. MRIs 60 min after the s.c. administration of 100 μg octreotide showed a 34.9 ± 6.2% (mean ± SD) reduction in relative enhancement in the selected liver metastases as compared to baseline. In 2 patients, however, there was no (significant) reduction in the relative enhancement in the selected liver metastases 60 min after the s.c. administration of 100 μg octreotide as compared to baseline. Only in 2 patients did the MRIs at 3 months show a decrease in relative enhancement in one of the selected liver metastases. At 3 months, with 100 μg octreotide s.c. t.i.d., there was no correlation between the change in relative enhancement on MRI and the change in 24-hour 5-HIAA excretion. There is thus only an acute effect of octreotide on the perfusion of liver metastases. This study further shows that contrast-enhanced dynamic MRI can be a very useful tool for studying hemodynamic effects of medical therapies on liver metastases in patients with metastatic midgut carcinoids.

Original languageEnglish (US)
Pages (from-to)41-48
Number of pages8
JournalNeuroendocrinology
Volume82
Issue number1
DOIs
StatePublished - Dec 1 2005

Fingerprint

Octreotide
Carcinoid Tumor
Magnetic Resonance Imaging
Neoplasm Metastasis
Liver
Gadolinium
Hemodynamics
Hydroxyindoleacetic Acid
Perfusion
Injections

Keywords

  • Carcinoid syndrome
  • Clinical neuroendocrinology
  • Liver
  • Magnetic resonance imaging
  • Neuroendocrine tumors
  • Octreotide
  • Somatostatin analogs

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Cellular and Molecular Neuroscience

Cite this

Zomerhuis, M. T., Hussain, S. M., Feelders, R. A., Van Der Lely, A. J., & De Herder, W. W. (2005). Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome. Neuroendocrinology, 82(1), 41-48. https://doi.org/10.1159/000090636

Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome. / Zomerhuis, Menno T.; Hussain, Shahid M.; Feelders, Richard A.; Van Der Lely, Aart Jan; De Herder, Wouter W.

In: Neuroendocrinology, Vol. 82, No. 1, 01.12.2005, p. 41-48.

Research output: Contribution to journalArticle

Zomerhuis, MT, Hussain, SM, Feelders, RA, Van Der Lely, AJ & De Herder, WW 2005, 'Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome', Neuroendocrinology, vol. 82, no. 1, pp. 41-48. https://doi.org/10.1159/000090636
Zomerhuis, Menno T. ; Hussain, Shahid M. ; Feelders, Richard A. ; Van Der Lely, Aart Jan ; De Herder, Wouter W. / Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome. In: Neuroendocrinology. 2005 ; Vol. 82, No. 1. pp. 41-48.
@article{175a2514b53d4e12b893f6483333424f,
title = "Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome",
abstract = "We have investigated the acute and sustained hemodynamic effects of octreotide on hepatic metastases of midgut carcinoids using contrast-enhanced dynamic magnetic resonance imaging (MRI). Seven patients with the carcinoid syndrome and metastasized midgut carcinoid tumors underwent functional dynamic multi-phase gadolinium-enhanced MRI of selected liver metastases at baseline and 60 min after the subcutaneous (s.c.) administration of 100 μg octreotide, and also after 3 months with three times daily (t.i.d.) 100 μg octreotide s.c. Baseline MRIs showed the typical aspect of carcinoid liver metastases with a very bright signal on the T2-weighted sequences and intense enhancement in the arterial phase after injection of gadolinium-diethylenetriamine-pentaacetate. MRIs 60 min after the s.c. administration of 100 μg octreotide showed a 34.9 ± 6.2{\%} (mean ± SD) reduction in relative enhancement in the selected liver metastases as compared to baseline. In 2 patients, however, there was no (significant) reduction in the relative enhancement in the selected liver metastases 60 min after the s.c. administration of 100 μg octreotide as compared to baseline. Only in 2 patients did the MRIs at 3 months show a decrease in relative enhancement in one of the selected liver metastases. At 3 months, with 100 μg octreotide s.c. t.i.d., there was no correlation between the change in relative enhancement on MRI and the change in 24-hour 5-HIAA excretion. There is thus only an acute effect of octreotide on the perfusion of liver metastases. This study further shows that contrast-enhanced dynamic MRI can be a very useful tool for studying hemodynamic effects of medical therapies on liver metastases in patients with metastatic midgut carcinoids.",
keywords = "Carcinoid syndrome, Clinical neuroendocrinology, Liver, Magnetic resonance imaging, Neuroendocrine tumors, Octreotide, Somatostatin analogs",
author = "Zomerhuis, {Menno T.} and Hussain, {Shahid M.} and Feelders, {Richard A.} and {Van Der Lely}, {Aart Jan} and {De Herder}, {Wouter W.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1159/000090636",
language = "English (US)",
volume = "82",
pages = "41--48",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome

AU - Zomerhuis, Menno T.

AU - Hussain, Shahid M.

AU - Feelders, Richard A.

AU - Van Der Lely, Aart Jan

AU - De Herder, Wouter W.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - We have investigated the acute and sustained hemodynamic effects of octreotide on hepatic metastases of midgut carcinoids using contrast-enhanced dynamic magnetic resonance imaging (MRI). Seven patients with the carcinoid syndrome and metastasized midgut carcinoid tumors underwent functional dynamic multi-phase gadolinium-enhanced MRI of selected liver metastases at baseline and 60 min after the subcutaneous (s.c.) administration of 100 μg octreotide, and also after 3 months with three times daily (t.i.d.) 100 μg octreotide s.c. Baseline MRIs showed the typical aspect of carcinoid liver metastases with a very bright signal on the T2-weighted sequences and intense enhancement in the arterial phase after injection of gadolinium-diethylenetriamine-pentaacetate. MRIs 60 min after the s.c. administration of 100 μg octreotide showed a 34.9 ± 6.2% (mean ± SD) reduction in relative enhancement in the selected liver metastases as compared to baseline. In 2 patients, however, there was no (significant) reduction in the relative enhancement in the selected liver metastases 60 min after the s.c. administration of 100 μg octreotide as compared to baseline. Only in 2 patients did the MRIs at 3 months show a decrease in relative enhancement in one of the selected liver metastases. At 3 months, with 100 μg octreotide s.c. t.i.d., there was no correlation between the change in relative enhancement on MRI and the change in 24-hour 5-HIAA excretion. There is thus only an acute effect of octreotide on the perfusion of liver metastases. This study further shows that contrast-enhanced dynamic MRI can be a very useful tool for studying hemodynamic effects of medical therapies on liver metastases in patients with metastatic midgut carcinoids.

AB - We have investigated the acute and sustained hemodynamic effects of octreotide on hepatic metastases of midgut carcinoids using contrast-enhanced dynamic magnetic resonance imaging (MRI). Seven patients with the carcinoid syndrome and metastasized midgut carcinoid tumors underwent functional dynamic multi-phase gadolinium-enhanced MRI of selected liver metastases at baseline and 60 min after the subcutaneous (s.c.) administration of 100 μg octreotide, and also after 3 months with three times daily (t.i.d.) 100 μg octreotide s.c. Baseline MRIs showed the typical aspect of carcinoid liver metastases with a very bright signal on the T2-weighted sequences and intense enhancement in the arterial phase after injection of gadolinium-diethylenetriamine-pentaacetate. MRIs 60 min after the s.c. administration of 100 μg octreotide showed a 34.9 ± 6.2% (mean ± SD) reduction in relative enhancement in the selected liver metastases as compared to baseline. In 2 patients, however, there was no (significant) reduction in the relative enhancement in the selected liver metastases 60 min after the s.c. administration of 100 μg octreotide as compared to baseline. Only in 2 patients did the MRIs at 3 months show a decrease in relative enhancement in one of the selected liver metastases. At 3 months, with 100 μg octreotide s.c. t.i.d., there was no correlation between the change in relative enhancement on MRI and the change in 24-hour 5-HIAA excretion. There is thus only an acute effect of octreotide on the perfusion of liver metastases. This study further shows that contrast-enhanced dynamic MRI can be a very useful tool for studying hemodynamic effects of medical therapies on liver metastases in patients with metastatic midgut carcinoids.

KW - Carcinoid syndrome

KW - Clinical neuroendocrinology

KW - Liver

KW - Magnetic resonance imaging

KW - Neuroendocrine tumors

KW - Octreotide

KW - Somatostatin analogs

UR - http://www.scopus.com/inward/record.url?scp=31444456446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31444456446&partnerID=8YFLogxK

U2 - 10.1159/000090636

DO - 10.1159/000090636

M3 - Article

C2 - 16391492

AN - SCOPUS:31444456446

VL - 82

SP - 41

EP - 48

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 1

ER -